2.90
price up icon2.84%   0.08
after-market 시간 외 거래: 2.90
loading
전일 마감가:
$2.82
열려 있는:
$2.81
하루 거래량:
106.17K
Relative Volume:
1.44
시가총액:
$41.45M
수익:
$486.00K
순이익/손실:
$-28.43M
주가수익비율:
-0.2627
EPS:
-11.04
순현금흐름:
$-26.75M
1주 성능:
+2.11%
1개월 성능:
+20.83%
6개월 성능:
+7.41%
1년 성능:
-27.86%
1일 변동 폭
Value
$2.79
$2.95
1주일 범위
Value
$2.65
$2.95
52주 변동 폭
Value
$1.57
$4.09

Vyne Therapeutics Inc Stock (VYNE) Company Profile

Name
명칭
Vyne Therapeutics Inc
Name
전화
800-775-7936
Name
주소
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Name
직원
10
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
VYNE's Discussions on Twitter

VYNE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
VYNE 2.90 41.45M 486.00K -28.43M -26.75M -11.04
VRTX 450.37 115.10B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.07B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.20B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 25.09B 3.30B -501.07M 1.03B 11.54

Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-12-06 재개 H.C. Wainwright Buy

Vyne Therapeutics Inc 주식(VYNE)의 최신 뉴스

pulisher
Nov 20, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

VYNE Therapeutics initiated with a Buy at BTIG on I&I potential - Yahoo Finance

Nov 19, 2024
pulisher
Nov 11, 2024

VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

VYNE Therapeutics Advances Clinical Pipeline in Q3 2024 - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

VYNE Therapeutics Reports Strong Pipeline Progress, $70.2M Cash Position Despite Q3 Loss | VYNE Stock News - StockTitan

Nov 07, 2024
pulisher
Oct 09, 2024

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - Simply Wall St

Oct 09, 2024
pulisher
Sep 26, 2024

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully - Yahoo Finance

Sep 26, 2024
pulisher
Sep 24, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

Shapiro Capital Management LLC Makes New Investment in NCR Voyix Co. (NYSE:VYX) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

(VYX) Long Term Investment Analysis - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Engine Capital Management LP Purchases Shares of 78,691 NCR Voyix Co. (NYSE:VYX) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

ZIGUP plc Optimistic as Vehicle Supply Improves - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

ZIGUP plc Optimistic as Vehicle Supply Rises - TipRanks

Sep 24, 2024
pulisher
Sep 23, 2024

Wix Is Set for Growth With Expanding Margins and Cash Flow, Analyst Upgrades Stock - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

What is Voyager Therapeutics Inc (VYGR) Stock Return on Shareholders’ Capital? - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Wix, GoDaddy in spotlight as Piper Sandler changes ratings on pair - Seeking Alpha

Sep 23, 2024
pulisher
Sep 23, 2024

Wix.com (NASDAQ:WIX) Upgraded by Piper Sandler to "Overweight" - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World

Sep 23, 2024
pulisher
Sep 20, 2024

Xylem Inc. (NYSE:XYL) Shares Sold by Virtu Financial LLC - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

A company insider recently bought 3,648 shares of NCR Voyix Corp [VYX]. Should You Buy? - Knox Daily

Sep 19, 2024
pulisher
Sep 14, 2024

HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Sep 14, 2024
pulisher
Sep 12, 2024

VYNE reports positive early trial results for inflammation drug - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202 - TipRanks

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE reports positive early trial results for inflammation drug By Investing.com - Investing.com UK

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

Sep 12, 2024
pulisher
Sep 03, 2024

VYNE Therapeutics to Participate in September Investor Conferences - StockTitan

Sep 03, 2024
pulisher
Aug 17, 2024

VYNE Therapeutics sees cash runway through end of 2025 - TipRanks

Aug 17, 2024
pulisher
Aug 17, 2024

VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Aug 16, 2024
pulisher
Aug 15, 2024

VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year - TipRanks

Aug 15, 2024
pulisher
Aug 14, 2024

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

Aug 14, 2024
pulisher
Aug 14, 2024

VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace

Aug 14, 2024
pulisher
Aug 08, 2024

Virtu Financial LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Aug 08, 2024
pulisher
Jul 24, 2024

VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World

Jul 24, 2024
pulisher
Jul 21, 2024

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way? - Simply Wall St

Jul 21, 2024
pulisher
Jul 16, 2024

VYNE Therapeutics secures UK patent for inflammation drug - Investing.com

Jul 16, 2024
pulisher
Jul 16, 2024

Latest Patent Grant Is Driving VYNE Therapeutics Stock Higher Today - News IMC

Jul 16, 2024
pulisher
Jul 16, 2024

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

Jul 16, 2024
pulisher
Jul 11, 2024

One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance

Jul 11, 2024
pulisher
Jul 09, 2024

VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz

Jul 09, 2024
pulisher
Jul 09, 2024

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan

Jul 09, 2024
pulisher
Jul 05, 2024

How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2% - Yahoo News Malaysia

Jul 05, 2024
pulisher
Jul 04, 2024

VYNE Therapeutics Insiders Are Down US$27k But Regain Some Losses - Simply Wall St

Jul 04, 2024
pulisher
Jul 03, 2024

VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease - Dermatology Times

Jul 03, 2024
pulisher
Jun 30, 2024

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June - Defense World

Jun 30, 2024
pulisher
Jun 28, 2024

Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket - Quantisnow

Jun 28, 2024
pulisher
Jun 26, 2024

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - StockTitan

Jun 26, 2024

Vyne Therapeutics Inc (VYNE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
자본화:     |  볼륨(24시간):